ImClone Investigational Site

Nashville, Tennessee 37232

0 studies enrolling now · 9 studies all time

What they study most

Advanced Solid Tumors, Breast Cancer, Carcinoma, Colon Cancer, Colorectal Cancer, Head and Neck Cancer, Metastatic Breast Cancer, Neuroendocrine Tumors, Prostate Cancer, Rectal Cancer

Studies at this site

• A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer — Completed
• A Study of Ramucirumab or Icrucumab in Colorectal Cancer — Completed
• A Study for Safety and Effectiveness of IMC-A12 by Itself or Combined With Antiestrogens to Treat Breast Cancer — Completed
• Study of IMC-A12, Alone or in Combination With Cetuximab, in Participants With Recurrent or Metastatic Squamous Cell Carcinoma (MSCC) of the Head and Neck — Completed
• A Study of Ramucirumab (IMC-1121B) in Combination With Eribulin Versus Eribulin Alone in Participants With Breast Cancer — Completed
• A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer — Completed
• A Study of IMC-A12 Every 2 Weeks in Patients With Tumors Who No Longer Respond to Treatment or No Treatment is Available — Completed
• Study of Irinotecan and Cetuximab Versus Irinotecan as Second-Line Treatment in Patients With Metastatic, EGFR-Positive Colorectal Cancer — Completed
• Study of Cetuximab, Oxaliplatin, 5-FU/LV Versus Oxaliplatin, 5-FU/LV in Patients With Previously Treated Metastatic, EGFR-Positive Colorectal Cancer — Completed